Qiagen (NYSE:QGEN) Receives $50.07 Average Price Target from Brokerages

Qiagen (NYSE:QGEN) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $50.07.

Several equities analysts have commented on the stock. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a research report on Thursday, October 17th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and set a $52.50 price objective (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 target price (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th.

Institutional Trading of Qiagen

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. Massmutual Trust Co. FSB ADV increased its stake in shares of Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the period. Geneos Wealth Management Inc. grew its holdings in Qiagen by 41.5% during the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after acquiring an additional 251 shares in the last quarter. CWM LLC increased its position in Qiagen by 11.5% during the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after purchasing an additional 287 shares during the period. Zurich Insurance Group Ltd FI raised its holdings in shares of Qiagen by 5.7% in the 3rd quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock valued at $239,000 after purchasing an additional 287 shares in the last quarter. Finally, National Bank of Canada FI lifted its position in shares of Qiagen by 1.2% in the 3rd quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock worth $1,155,000 after purchasing an additional 308 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen Price Performance

NYSE:QGEN opened at $43.76 on Monday. The business’s 50-day moving average is $43.80 and its 200 day moving average is $43.26. Qiagen has a 12 month low of $40.15 and a 12 month high of $49.30. The company has a market capitalization of $9.71 billion, a P/E ratio of 109.09, a P/E/G ratio of 3.10 and a beta of 0.36. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.43% and a net margin of 4.73%. On average, equities research analysts forecast that Qiagen will post 2.23 earnings per share for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.